Does Catalyst Pharmaceuticals Still Offer Value After Firdapse Franchise Expansion and Share Price Surge?

• If you are wondering whether Catalyst Pharmaceuticals is still attractive at around $23 a share, or if most of the upside is already reflected in the price, you are not alone.
• Despite a modest slip of 1.4% over the past week, the stock is up 8.2% over the last month, 7.3% year to date and 539.9% over five years, which suggests investors have been steadily re rating its prospects.
• Recent attention on its expanding rare disease portfolio and ongoing efforts to defend and extend its Firdapse franchise have helped frame the stock as a focused specialist rather than a one drug story. At the same time, regulatory and competitive updates across the neuromuscular and central nervous system space have influenced sentiment as investors reassess both growth potential and risk.
• In our checks, Catalyst scores a perfect 6 out of 6 on valuation, flagging it as undervalued across every metric we track. In the next sections we will walk through those methods, then finish with a more intuitive way to think about what the market might be willing to pay for this business.

Find out why Catalyst Pharmaceuticals's 6.5% return over the last year is lagging behind its peers.

Approach 1: Catalyst Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company is worth by projecting the cash it can generate in the future and then discounting those cash flows back to today to account for risk and time.

For Catalyst Pharmaceuticals, the model starts with last twelve months Free Cash Flow of about $151.7 million and uses analyst forecasts for the next few years, then extrapolates further growth beyond that. On this basis, Simply Wall St projects Free Cash Flow could reach roughly $374.6 million in 2035, reflecting steady but moderating expansion as the business matures.

When all of those future cash flows are discounted back to today using a 2 Stage Free Cash Flow to Equity framework, the resulting intrinsic value is around $60.02 per share. Compared with the current share price near $23, the DCF suggests the stock is trading at about a 61.5% discount to its estimated fair value. This indicates potential upside if those cash flow projections prove accurate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Catalyst Pharmaceuticals is undervalued by 61.5%. Track this in your watchlist or portfolio, or discover 917 more undervalued stocks based on cash flows.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Catalyst Pharmaceuticals.

Approach 2: Catalyst Pharmaceuticals Price vs Earnings

For profitable companies like Catalyst Pharmaceuticals, the price to earnings, or PE, ratio is a helpful way to see how much investors are willing to pay today for each dollar of current earnings. What counts as a normal PE depends on how quickly profits are expected to grow and how risky those earnings are, with faster growth and lower risk usually justifying a higher multiple.

Catalyst trades on a PE of about 13.1x, which is well below both the broader Biotechs industry average of roughly 19.6x and the peer group average near 63.0x. To move beyond simple comparisons, Simply Wall St uses a proprietary Fair Ratio that estimates what PE the market might reasonably pay given factors such as Catalyst’s earnings growth outlook, margins, size and risk profile. For Catalyst, that Fair Ratio is 18.0x, implying the shares trade at a discount to what its fundamentals would typically warrant on this framework.

Taken together, the gap between the current 13.1x and the Fair Ratio of 18.0x suggests the stock still looks attractively priced on an earnings basis.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1443 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Catalyst Pharmaceuticals Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way to connect your view of Catalyst Pharmaceuticals with the numbers behind it.

A Narrative is your story about a company, translated into assumptions about future revenue, earnings and margins, so that the story is directly linked to a financial forecast and, ultimately, to a fair value estimate.

On Simply Wall St, Narratives sit inside the Community page and are used by many investors as an accessible tool. They can help you think about whether to buy or sell by continuously comparing your fair value estimate to the current share price.

Because Narratives are updated dynamically as new information arrives, such as earnings results or major drug updates, your fair value view of Catalyst can adjust automatically alongside the latest data rather than staying fixed.

For example, one investor might build a Narrative that supports a fair value near the highest published target of about $40 if they believe FIRDAPSE, AGAMREE and new deals can drive durable growth. Another might align more closely with the most cautious view around $31 if they focus more on patent risks, generic competition and a thinner late stage pipeline.

Do you think there's more to the story for Catalyst Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com